Rudd International Inc. bought a new position in Bristol-Myers Squibb Co (NYSE:BMY) in the second quarter, Holdings Channel.com reports. The institutional investor bought 4,748 shares of the biopharmaceutical company’s stock, valued at approximately $215,000.
A number of other institutional investors have also recently made changes to their positions in the business. Lodestar Investment Counsel LLC IL raised its stake in Bristol-Myers Squibb by 5.2% in the 2nd quarter. Lodestar Investment Counsel LLC IL now owns 113,720 shares of the biopharmaceutical company’s stock valued at $5,157,000 after purchasing an additional 5,579 shares during the last quarter. Perella Weinberg Partners Capital Management LP grew its position in Bristol-Myers Squibb by 10.9% during the first quarter. Perella Weinberg Partners Capital Management LP now owns 19,431 shares of the biopharmaceutical company’s stock worth $99,000 after buying an additional 1,905 shares in the last quarter. Stephens Inc. AR boosted its holdings in Bristol-Myers Squibb by 30.7% during the first quarter. Stephens Inc. AR now owns 216,532 shares of the biopharmaceutical company’s stock valued at $10,331,000 after purchasing an additional 50,798 shares in the last quarter. Nachman Norwood & Parrott Inc boosted its holdings in Bristol-Myers Squibb by 3.5% during the second quarter. Nachman Norwood & Parrott Inc now owns 50,388 shares of the biopharmaceutical company’s stock valued at $2,285,000 after purchasing an additional 1,687 shares in the last quarter. Finally, Edge Wealth Management LLC boosted its holdings in Bristol-Myers Squibb by 217.7% during the second quarter. Edge Wealth Management LLC now owns 10,007 shares of the biopharmaceutical company’s stock valued at $452,000 after purchasing an additional 6,857 shares in the last quarter. Institutional investors and hedge funds own 77.37% of the company’s stock.
In related news, Director Robert J. Bertolini acquired 11,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was purchased at an average price of $44.72 per share, for a total transaction of $491,920.00. Following the transaction, the director now directly owns 11,397 shares of the company’s stock, valued at approximately $509,673.84. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is owned by insiders.
Shares of BMY traded up $1.23 on Friday, hitting $46.98. The company’s stock had a trading volume of 9,425,900 shares, compared to its average volume of 14,942,915. The company has a market capitalization of $74.84 billion, a PE ratio of 11.80, a PEG ratio of 2.26 and a beta of 0.73. The company has a debt-to-equity ratio of 1.51, a current ratio of 3.88 and a quick ratio of 3.75. Bristol-Myers Squibb Co has a fifty-two week low of $42.48 and a fifty-two week high of $63.69. The company has a 50 day moving average price of $45.33 and a 200 day moving average price of $47.45.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, topping the consensus estimate of $1.06 by $0.12. The business had revenue of $6.27 billion for the quarter, compared to the consensus estimate of $6.10 billion. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. Bristol-Myers Squibb’s revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.01 EPS. On average, equities analysts forecast that Bristol-Myers Squibb Co will post 4.26 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were issued a $0.41 dividend. This represents a $1.64 annualized dividend and a dividend yield of 3.49%. The ex-dividend date of this dividend was Wednesday, July 3rd. Bristol-Myers Squibb’s payout ratio is currently 41.21%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Further Reading: The Discount Rate – What You Need to Know
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.